JPWO2020123900A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020123900A5 JPWO2020123900A5 JP2021534126A JP2021534126A JPWO2020123900A5 JP WO2020123900 A5 JPWO2020123900 A5 JP WO2020123900A5 JP 2021534126 A JP2021534126 A JP 2021534126A JP 2021534126 A JP2021534126 A JP 2021534126A JP WO2020123900 A5 JPWO2020123900 A5 JP WO2020123900A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- less
- baseline
- cerebral palsy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 208000012661 Dyskinesia Diseases 0.000 claims 15
- 206010008129 cerebral palsy Diseases 0.000 claims 11
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 8
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 8
- 229910052805 deuterium Inorganic materials 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- MKJIEFSOBYUXJB-VFJJUKLQSA-N (3r,11br)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical compound C1CN2C[C@@H](CC(C)C)C(=O)C[C@@H]2C2=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C2 MKJIEFSOBYUXJB-VFJJUKLQSA-N 0.000 claims 4
- 229950005031 deutetrabenazine Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 206010008748 Chorea Diseases 0.000 claims 2
- 208000012601 choreatic disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000000632 dystonic effect Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779232P | 2018-12-13 | 2018-12-13 | |
| US62/779,232 | 2018-12-13 | ||
| US201962801450P | 2019-02-05 | 2019-02-05 | |
| US62/801,450 | 2019-02-05 | ||
| PCT/US2019/066150 WO2020123900A1 (en) | 2018-12-13 | 2019-12-13 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519007A JP2022519007A (ja) | 2022-03-18 |
| JP2022519007A5 JP2022519007A5 (https=) | 2022-12-22 |
| JPWO2020123900A5 true JPWO2020123900A5 (https=) | 2022-12-22 |
Family
ID=69173404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534126A Pending JP2022519007A (ja) | 2018-12-13 | 2019-12-13 | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11324732B2 (https=) |
| EP (1) | EP3893876A1 (https=) |
| JP (1) | JP2022519007A (https=) |
| KR (1) | KR20210114946A (https=) |
| CN (1) | CN113395966A (https=) |
| AU (1) | AU2019395250A1 (https=) |
| BR (1) | BR112021011386A2 (https=) |
| CA (1) | CA3123393A1 (https=) |
| CL (1) | CL2021001554A1 (https=) |
| IL (1) | IL283920A (https=) |
| MX (1) | MX2021007063A (https=) |
| SG (1) | SG11202106344SA (https=) |
| TW (1) | TWI784220B (https=) |
| WO (1) | WO2020123900A1 (https=) |
| ZA (1) | ZA202104786B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI784220B (zh) * | 2018-12-13 | 2022-11-21 | 美商奧斯拜客斯製藥有限公司 | 腦性麻痺運動障礙之治療方法 |
| IL307678A (en) * | 2021-04-15 | 2023-12-01 | Neurocrine Biosciences Inc | Methods of administering certain VMAT2 inhibitors |
| JP2024514873A (ja) * | 2021-04-15 | 2024-04-03 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | デューテトラベナジンおよびｃｙｐ２ｄ６阻害剤の併用投与のための方法 |
| WO2024090922A1 (ko) | 2022-10-24 | 2024-05-02 | 주식회사 디자인셀 | 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010044981A2 (en) * | 2008-09-18 | 2010-04-22 | Auspex Pharmaceutical ,Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| AU2015200243B2 (en) * | 2009-06-24 | 2016-09-29 | Egalet Ltd | Controlled release formulations |
| CA2801061A1 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| CN104684555A (zh) | 2012-09-18 | 2015-06-03 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学 |
| HRP20221106T1 (hr) * | 2015-03-06 | 2022-11-25 | Auspex Pharmaceuticals, Inc. | Postupci liječenja abnormalnih nevoljnih poremećaja pokreta |
| UA127052C2 (uk) * | 2017-03-15 | 2023-03-29 | Оспекс Фармасьютікалс, Інк. | Аналоги деутетрабеназину, їхнє отримання та застосування |
| TWI784220B (zh) * | 2018-12-13 | 2022-11-21 | 美商奧斯拜客斯製藥有限公司 | 腦性麻痺運動障礙之治療方法 |
-
2019
- 2019-12-13 TW TW108145866A patent/TWI784220B/zh active
- 2019-12-13 AU AU2019395250A patent/AU2019395250A1/en not_active Abandoned
- 2019-12-13 CA CA3123393A patent/CA3123393A1/en active Pending
- 2019-12-13 WO PCT/US2019/066150 patent/WO2020123900A1/en not_active Ceased
- 2019-12-13 BR BR112021011386-0A patent/BR112021011386A2/pt not_active Application Discontinuation
- 2019-12-13 KR KR1020217021438A patent/KR20210114946A/ko not_active Abandoned
- 2019-12-13 JP JP2021534126A patent/JP2022519007A/ja active Pending
- 2019-12-13 SG SG11202106344SA patent/SG11202106344SA/en unknown
- 2019-12-13 US US16/713,917 patent/US11324732B2/en active Active
- 2019-12-13 MX MX2021007063A patent/MX2021007063A/es unknown
- 2019-12-13 EP EP19839001.5A patent/EP3893876A1/en not_active Withdrawn
- 2019-12-13 CN CN201980089635.4A patent/CN113395966A/zh active Pending
-
2021
- 2021-06-11 CL CL2021001554A patent/CL2021001554A1/es unknown
- 2021-06-12 IL IL283920A patent/IL283920A/en unknown
- 2021-07-08 ZA ZA2021/04786A patent/ZA202104786B/en unknown
-
2022
- 2022-04-12 US US17/718,441 patent/US20220409597A1/en not_active Abandoned
-
2023
- 2023-06-28 US US18/343,197 patent/US20240082225A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Crosby et al. | Amantadine in Parkinson's disease | |
| JP7475398B2 (ja) | 医学療法におけるセマグルチド | |
| KR102040752B1 (ko) | 류마티스 관절염을 치료 또는 예방하는 약물 제조에서 폴리펩타이드의 응용 | |
| JP7436524B2 (ja) | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 | |
| CN103458899A (zh) | 治疗阻塞性睡眠呼吸暂停的方法 | |
| CN102302723A (zh) | 一种止咳化痰的中药制剂 | |
| JPWO2020123900A5 (https=) | ||
| JPH08512311A (ja) | 慢性疲労症候群治療用ヒ素医薬 | |
| KR20100038061A (ko) | 리마프로스트를 함유하는, 암화학 요법에 기인하는 말초신경장애 예방, 치료 및/또는 증상 경감제 | |
| WO2017101696A1 (zh) | 治疗急慢性呼吸困难的西药组合物及其制备方法 | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| Hanson | Cough mixtures-an overview | |
| CN116870159A (zh) | 一种用于水痘和带状疱疹皮肤病的外用软膏剂及制备方法 | |
| CN1302799C (zh) | 一种治疗病毒性心肌炎的口服中药组合物 | |
| JP2020514347A (ja) | チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤 | |
| CN108465061A (zh) | 一种用于治疗颜面再发性皮炎的药物组合物及其制备方法和用途 | |
| CN102406778A (zh) | 治疗阿尔茨海默型痴呆的中药组合物及其制备方法 | |
| US20230099229A1 (en) | Methods of treating multiple sclerosis | |
| AU2015305430A1 (en) | Method for treating hyperhidrosis | |
| JPH0517358A (ja) | 睡眠誘起性無呼吸症治療剤 | |
| TW200418447A (en) | New method for treating urinary disorders | |
| CN105327092A (zh) | 一种治疗颈源性失眠的中药组合物及其应用 | |
| JP6188784B2 (ja) | 炎症性および免疫性疾患の治療のための組成物 | |
| JPWO2022093724A5 (https=) | ||
| WO2017211182A1 (zh) | 一种预防或治疗炎性疾病的药物组合物 |